Search in the Abstract Database

Search Abstracts 2012

* = Presenting author

P229. Cell therapy and quality of life of patients with inflammatory bowel disease

O. Boldyreva1, O. Knyazev1, I. Gribanov2, I. Ruchkina1, L. Lazebnik1, A. Konoplyannikov3

1Central Research Institute of Gastroenterology, Moscow, Russian Federation; 2Polyclinic 150 of Moscow, Russian Federation; 3Medical Radiological Research Center of Russian Academy of Medical Sciences, Obninsk, Russian Federation

Background: Evaluation of physical, psychological and social well-being of patients with ulcerative colitis (UC) and Crohn's disease (CD) at different stages of the disease is used to develop treatments and rehabilitation programs. To assess the quality of life (QL) in patients with chronic inflammatory bowel disease (IBD) in the acute stage and one year after the standard anti-inflammatory therapy, combined therapy with the use of culture mesenchymal stromal cells (MSCs) and infliximab therapy.

Methods: IBD patient surveys were made using a specialized international questionnaire to identify patients with IBD QL (IBDQ) (maximum total value – 224 points). Of the 90 patients with IBD, formed the study group QL in acute disease, 35 patients (38.8%) suffered from CD, 55 (61.2%) – UC, 53 of them (58.9%) males and 37 (41.1%) – females. The median age was 35.2±1.2 years. The average duration of illness of persons interviewed was 9 years old. Patients were divided into age groups as follows: 18–24 – 21 (23.3%), 25–44 – 45 (50%), aged 45 and above-24 (26.7%). A year later, the surveys were 31 patients (group 1) after therapy with 5‑aminosalicylic acid (5-ASA), glucocorticosteroids (GCS), 29 patients (group 2), which carried out a systemic transplantation of mesenchymal stromal cells and 27 patients (group 3), treated with infliximab.

Results: 100% of the observed decrease in QL of patients with IBD in the period of exacerbation. According to the IBDQ average QL in patients with UC and CD was 118.1±11.5 points. During the remission rate was significantly improved QL in 1‑t group to an average of 169.7±22.3 (p < 0.05). However, there was a significant difference between patients who received 5‑ASA drugs (n = 7) and patients who received long-term corticosteroids (n = 24) – 184.8±22.6 and 154.7±21.1, respectively (p = 0.03). The level of QL in 2‑nd group patients was 198.6±26.3 points, which was significantly higher than in 1‑st group (p < 0.05). In the 3‑d group – 202.4±26.8 balls, which also had a significant difference from 1‑st group patients with IBD (p < 0.05). Differences in terms of QL between the 2‑nd and 3‑d groups was not (p = 0.6).

Conclusions: All the patients had inflammatory bowel disease during exacerbation has reduced quality of life. The results indicate a higher quality of life in patients with IBD who had received biological therapy – mesenchymal stromal cells and infliximab, than in patients treated with standard anti-inflammatory therapy.